Get In Touch
Have any questions or comments about the content you see on this page?
October 28, 2021
Today we announced the planned Chief Executive Officer transition of John Maraganore, Ph.D., to Dr. Yvonne Greenstreet, at year-end 2021. Yvonne is currently Alnylam's President and Chief Operating Officer. John has served as Alnylam's CEO since our founding in 2002. He will support the leadership transition in a consulting capacity through March 31, 2022 and will continue to contribute to Alnylam’s success as a member of the company’s Scientific Advisory Board. Effective immediately, Yvonne has been appointed to the Alnylam Board of Directors as part of the planned succession.
I greatly look forward to leading the remarkable team at Alnylam, working with our Executive Chair and the Board closely, as we advance the company in its next exciting chapter. Indeed, I believe that Alnylam is well on its way toward achieving its P5x25 aspirations of building a top-tier biotech, and I’m confident that our continued leadership of RNAi therapeutics and commitment to innovation for patients will guide us for the future. – Dr. Yvonne Greenstreet, incoming Alnylam CEO
Yvonne joined Alnylam in 2016 as Chief Operating Officer and was promoted to President and COO in 2020. She has more than 25 years of experience in the biopharmaceutical industry, driving strategy and innovation, bringing transformative medicines to patients, and building successful businesses in the US, Europe and globally. Between 2011 and 2013, Yvonne was Senior Vice President and Head of Medicines Development at Pfizer. Prior to Pfizer, she was at GlaxoSmithKline plc for 18 years, where she was Senior Vice President and Chief of Strategy for Research and Development. She had previously been in various positions of increasing responsibility at GSK, including Senior Vice President for Medicines Development and Chief Medical Officer for Europe. Yvonne trained as a physician and earned her medical degree (MBChB) from the University of Leeds in the UK. She also holds an MBA from INSEAD Business school in France. Yvonne is on the several boards of directors of and is a member of the Scientific Advisory Committee of the Bill and Melinda Gates Foundation and is a member of the Discovery Council of Harvard Medical School. You can read Yvonne's full bio here.
"On behalf of Alnylam’s Board, we are deeply grateful to John’s remarkable and storied leadership of Alnylam for all these years. There’s no doubt that John is both the architect and the inspiration of Alnylam’s success to this point in the company’s journey,” said Michael Bonney, Alnylam Executive Chair. “As we prepare for Alnylam’s continued leadership and execution on our P5x25 business strategy, we are very excited about Yvonne Greenstreet as our future CEO. With a continued commitment to innovation and patients, Yvonne brings enormous experience to grow and scale Alnylam as a leading global biopharmaceutical company.
Read more about this announcement in the press release.
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.Proceed to Site